TOP STORIES

• BUSINESS Nichi-Iko Seeks Debt Workout amid US Pipeline Delays and Quality Woes, but President to Stay
  May 16, 2022

• BUSINESS Sumitomo Pharma Likely to Miss 5-Year Biz Targets as COVID Hobbles US Launches
  May 16, 2022

• REGULATORY Japan Clears Bill to Create Emergency Approval System, Enforcement Slated by Month-End
  May 13, 2022

• BUSINESS Shionogi Books 110 Billion Yen Sales for Yet-to-Be-Approved COVID Pill, Vaccine: FY2022 Outlook
  May 12, 2022

• BUSINESS Opdivo Projected to Grow 38% to 155 Billion Yen, but Ono Chief Sees No Re-Pricing
  May 12, 2022

• BUSINESS Jardiance Will Come Back as No. 1 in Japan SGLT2 Space after CKD Launch: NBI Chair
  May 11, 2022

• COMMENTARY Foreign Pharma Growing Vocal against Japan’s Pricing Policy, Flags Return of Drug Lag
  May 10, 2022

• ACADEMIA Difficult-to-Quantify Factors Should Be Reflected in Drug Prices to Establish VBP: Health Economist
  May 9, 2022

• REGULATORY Maruho’s Rozex in Line for Rosacea Nod in Japan
  May 9, 2022

• BUSINESS Astellas Logs 1st Sales Growth in 3 Years in FY2021; Chairman Hatanaka to Bow Out
  April 28, 2022

• REGULATORY Japan Panel OKs Second Booster for Age 60-Plus, and High-Risk Adults
  April 28, 2022

• REGULATORY Novavax COVID-19 Jab OK’ed for 1st to 3rd Shot Use under Free Program
  April 28, 2022

• ORGANIZATION JPMA Think Tank Analyzing Cause of Expanding Drug Lag, Over 70% of US/EU Approved Meds Not Available in Japan
  April 27, 2022

• BUSINESS Japan Drug Makers Revving Up HR, Pay System Reforms; Eisai Mulling No Daily Allowance for Sales Reps
  April 27, 2022

• BUSINESS Sumitomo Scraps Daily Allowance for Sales Reps, Introduces Division Bonus to Boost Productivity
  April 26, 2022

• BUSINESS Chugai’s Q1 Sales Double on Ronapreve Bonanza, Brisk Hemlibra Export
  April 26, 2022

• REGULATORY Japan Panel OKs Comirnaty, Spikevax for 4th Shot, Use Limited to High-Risk People
  April 26, 2022

• REGULATORY SCARDA Provost Confident about Japanese Technologies, Wants to Mediate Company Matching
  April 25, 2022

• BUSINESS MSD Japan’s Sales Surge 7.5% in 2021, 1.5% Growth If Lagevrio Excluded: President
  April 22, 2022

• BUSINESS GSK Japan Chief Has High Hopes for Shingrix, Blenrep, RSV Jab as Future Growth Drivers
  April 21, 2022

ページ

• « 先頭
• ‹ Prev
• …
• 68
• 69
• 70
• 71
• 72
• 73
• 74
• 75
• 76
• …
• Next ›
• 最終 »